ProCE Banner Activity

Should We Be Concerned About Viral Rebound With Antiviral Agents?

Podcast Episodes
Listen as expert faculty discuss COVID-19 rebound, related to and independent of COVID-19 antiviral treatment.

Released: December 30, 2022

Expiration: December 29, 2023

Share

Faculty

Fernando Carnavali

Fernando Carnavali, MD

Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Mount Sinai Health System
New York, New York

Rasika Karnik

Rasika Karnik, MS, MD

Assistant Professor
Division of Primary Care, Department of Internal Medicine
University of Chicago
Medical Director
Post-Covid Recovery Clinic
Chicago, Illinois

Renslow Sherer

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Joseph Torrisi

Joseph Torrisi, PharmD, BCIDP

Clinical Pharmacy Specialist, Infectious Diseases
Pharmacy
Grady Health System
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Pfizer, Inc.

Faculty Disclosure

Primary Author

Fernando Carnavali, MD

Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Mount Sinai Health System
New York, New York

Fernando Carnavali, MD, has no relevant financial relationships to disclose.

Rasika Karnik, MS, MD

Assistant Professor
Division of Primary Care, Department of Internal Medicine
University of Chicago
Medical Director
Post-Covid Recovery Clinic
Chicago, Illinois

Rasika Karnik, MS, MD: consultant/advisor/speaker: Gilead Sciences.

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Renslow Sherer, MD: unrestricted research grant: Gilead Sciences.

Joseph Torrisi, PharmD, BCIDP

Clinical Pharmacy Specialist, Infectious Diseases
Pharmacy
Grady Health System
Atlanta, Georgia

Joseph Torrisi, PharmD, BCIDP, has no relevant financial relationships to disclose.